https://trial.medpath.com/news/d4ac6a10c78128e8/chmp-backs-novel-therapies-onpattro-for-hattr-and-symkevi-for-cystic-fibrosis 2018-07-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4bb945ef01d5f2b7/alder-biopharmaceuticals-to-showcase-eptinezumab-s-efficacy-in-migraine-prevention-at-ahs-meeting 2018-07-05T08:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/cdfd446a5ca65f24/sanofi-establishes-eur66-million-global-r-d-hub-in-chengdu-expanding-china-research-footprint 2018-07-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/79391824aaedca8e/genetic-variants-and-their-impact-on-clinical-responses-to-treatments 2018-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b71712cd2852e06a/vedolizumab-a-new-therapeutic-option-for-inflammatory-bowel-disease 2018-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cabfb11783d2bdc1/pfizer-amgen-and-sanofi-partner-to-leverage-blockchain-technology-in-clinical-trials 2018-06-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8dcc21816ad23e35/rising-demand-for-comparator-clinical-trials-reshapes-drug-development-landscape 2018-06-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/66233595a82a3bb9/first-immunotherapy-success-in-prostate-cancer-shows-promise-for-dna-repair-deficient-tumors 2018-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ec24e1075f65d48a/landmark-tailorx-trial-shows-70-of-early-stage-breast-cancer-patients-can-safely-skip-chemotherapy 2018-06-03T11:50:32+00:00 weekly 0.7 https://trial.medpath.com/news/8fab6863d42b0ea1/gsk-partners-with-cloud-pharmaceuticals-to-accelerate-drug-discovery-through-ai-technology 2018-05-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/97ef5e66d492c3c4/neuclone-gibt-praklinische-ergebnisse-von-biosimilar-kandidaten-fur-stelara-r-ustekinumab-bekannt 2018-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0970aef447c7d79b/gene-editing-restores-dystrophin-expression-in-a-canine-model-of 2018-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d958079ece38ff95/a-multicenter-prospective-single-arm-open-label 2018-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b467814bc2dc4992/novartis-sandoz-partners-with-pear-therapeutics-to-combat-substance-use-disorders-with-digital-solutions 2018-04-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0ba7a82fd003b911/alder-biopharmaceuticals-to-present-new-phase-3-migraine-prevention-data-for-eptinezumab 2018-04-18T14:31:23+00:00 weekly 0.7 https://trial.medpath.com/news/67b95b49d93080fc/blockchain-technology-poised-to-transform-pharmaceutical-supply-chain-security-and-traceability 2018-04-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/955b47451d510b43/survey-reveals-critical-gap-in-patient-engagement-across-clinical-trial-industry 2018-04-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/28f43243eb61e03e/fda-rejects-teva-and-celltrion-s-biosimilars-for-rituxan-and-herceptin-due-to-manufacturing-issues 2018-04-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/456e56c32a348032/nivolumab-plus-ipilimumab-may-be-a-new-first-line 2018-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6ee5af08238f063b/final-5-year-results-of-the-phase-2-pace-trial-for-cml-and-ph-all-patients 2018-03-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4fd2af62a06e6dcb/nice-rejects-cenegermin-for-rare-eye-disease-citing-cost-concerns 2018-03-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/350661696fea29f4/pipeline-watch-phase-iii-starts-with-oxabact-imeglimin-and 2018-03-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e597099b22bbb8fc/fda-grants-breakthrough-device-status-to-3i-diagnostics-rapid-blood-infection-test 2018-03-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a96167bbfa474ee1/overly-restrictive-clinical-trial-exclusion-criteria-may-block-patients 2018-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/30d97167e93b48d8/oncolytic-viruses-gain-momentum-in-cancer-treatment-following-merck-s-394m-viralytics-acquisition 2018-02-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f67909bf2e91d123/abbvie-s-elagolix-demonstrates-significant-efficacy-in-two-phase-3-trials-for-uterine-fibroids 2018-02-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/56a25f6c881197f4/ai-blockchain-and-big-data-new-technologies-promise-to-slash-pharmaceutical-r-d-costs 2018-02-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ffc397a13ff5a944/stanford-researchers-develop-injectable-cancer-vaccine-that-eliminates-tumors-in-mice 2018-01-31T19:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8f93ef55141dadac/former-eli-lilly-executive-alex-azar-sworn-in-as-us-health-secretary-pledges-to-combat-high-drug-prices 2018-01-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/00c4502871e13ae5/clinical-trial-outsourcing-set-to-reach-72-by-2020-as-industry-embraces-cro-partnerships 2018-01-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0b2002bc964707b1/roche-s-ocrevus-to-match-novartis-s-gilenya-pricing-in-uk-ms-market 2018-01-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/818d5039f8a3a184/janssen-to-address-key-challenges-in-drug-device-combination-product-development-at-pre-filled-syringes-conference 2018-01-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ac4be880d5d39d29/study-on-telisotuzumab-vedotin-shows-promise-for-c-met-positive-nsclc-patients 2018-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/364c59bfd6c88778/fda-grants-breakthrough-therapy-designation-to-lenvima-keytruda-combination-for-advanced-renal-cell-carcinoma 2018-01-09T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/c6deffe53262b873/landiolol-pharmacology-and-its-use-for-rate-control-in-atrial 2018-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/66966ff78c7e53be/futura-medical-s-med2005-shows-promise-as-rapid-acting-topical-treatment-for-erectile-dysfunction 2018-01-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c7be7a92ef5edfd1/eli-lilly-agrees-to-acquire-siteone-therapeutics-for-up-to-1-billion-in-non-opioid-pain-therapy-deal 2018-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ebfeea97ebc0aab9/study-finds-internal-cooling-offers-better-survival-outcomes-for-post-cardiac-arrest-patients 2018-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c26da6de6d0890a8/articles-archives-drug-hunter 2018-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0c527d3eea0815e7/uk-survey-reveals-complex-landscape-of-pharmaceutical-market-access-challenges 2017-12-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6e8a5c0bc3d982cf/clinical-database-delays-significantly-impact-trial-timelines-tufts-study-reveals 2017-12-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/306c13e71d9f780b/protection-of-the-human-gut-microbiome-from-antibiotics 2017-11-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/81dfd21bb95dfb75/leading-pharma-companies-and-regulators-to-convene-at-10th-annual-adaptive-clinical-trials-conference 2017-11-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c1e55d9f10131a01/gsk-s-investigational-bcma-antibody-drug-conjugate 2017-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4ede1b4211fcd82e/china-s-pharmaceutical-r-d-evolution-regulatory-reforms-signal-new-era-for-drug-development 2017-10-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a5793c996f7269e0/european-oncology-biosimilars-set-to-generate-eur2-billion-in-healthcare-savings-by-2021 2017-10-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6dfb6b680c1924b9/fda-approves-mylan-s-generic-versions-of-copaxone-for-multiple-sclerosis-treatment 2017-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/33f346cdc648dc5d/advancing-traumatic-brain-injury-treatment-through-the-ted-initiative 2017-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4ced2357ff2dff0a/springworks-therapeutics-launches-with-103m-to-advance-pfizer-s-rare-disease-portfolio 2017-09-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/42dd67cb36f9bcd5/ibrutinib-shows-promise-in-treating-chronic-graft-versus-host-disease 2017-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4ad6f9764c022591/novartis-s-kymriah-breakthrough-car-t-therapy-priced-at-475000-sparks-value-debate 2017-09-06T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/171ee89382fd3c01/catalyst-biosciences-announces-positive-factor-ix-clinical-data 2017-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/90a15f93343c5bd8/phase-2-trial-shows-high-efficacy-of-boven-regimen-in-treating-chronic-lymphocytic-leukaemia 2017-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b1d5d5571596a964/efficacy-and-safety-of-a-triple-combination-of-atezolizumab 2017-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/527267af063d6fd1/strategic-approaches-to-securing-market-access-for-orphan-drugs-beyond-hta-approval 2017-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2b1559fcee10d94f/medical-affairs-evolution-eisai-s-kirk-shepard-leads-transformation-towards-patient-centric-pharma 2017-08-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8dd68a0aa0989333/alicaforsen-shows-promise-in-treating-inflammatory-bowel-disease 2017-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d334a9265b3a45db/immunotherapy-drugs-unexpectedly-restore-hair-color-in-lung-cancer-patients 2017-07-27T16:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/7a63d08d56f1091b/fda-grants-full-approval-to-blinatumomab-for-b-cell-precursor-all 2017-07-12T18:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/9143edb06197a52c/patient-centric-approaches-and-technology-reshape-clinical-trial-landscape-industry-experts-report 2017-07-12T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7fc3da62c74aaa3c/manali-kamdar-s-contributions-to-lymphoma-treatment-research 2017-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1874b052feb7a565/soleno-therapeutics-announces-successful-completion-of-fda-meeting-for-dccr-in-prader-willi-syndrome 2017-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f827fab670ac6303/gsk-partners-with-exscientia-in-ps33m-ai-driven-drug-discovery-alliance 2017-07-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b6d679f075dbbd6b/alder-biopharmaceuticals-announces-positive-eptinezumab-phase-3-results-for-migraine-prevention 2017-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/48d9139caa84c7ec/immunotherapy-for-glioblastoma-shows-promise-in-early-study 2017-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f826656b43adbdc7/clinical-trial-data-sharing-initiatives-drive-innovation-and-efficiency-in-drug-development 2017-06-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/81a6c4f9d09aa56e/actinium-pharmaceuticals-granted-orphan-designation-from 2017-05-24T09:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/0bf3c60925c3ec7a/dynamic-consent-platforms-revolutionizing-clinical-trial-participation-and-data-management 2017-05-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ed1dbfdf4a2ba05f/celltrion-pursues-novel-multi-brand-strategy-for-rituximab-biosimilar-in-eu-market 2017-05-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4a68c87872780c36/tirzepatide-shows-superior-weight-loss-efficacy-over-semaglutide-in-real-world-study 2017-05-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c11bb7436a0436c4/fda-approves-fourth-alk-inhibitor-for-lung-cancer 2017-05-05T18:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/87cdf2700920bc62/review-of-the-drug-trials-snapshots-program-of-the-us 2017-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4d514daf70c2ab38/immunotherapy-for-glioblastoma-shows-promise-in-early-study 2017-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9c62c8f61b3ec5ca/benevolentai-partners-with-mrc-technology-to-accelerate-ai-driven-drug-discovery 2017-04-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5febf077cd8835b8/jim-mellon-backs-insilico-medicine-s-ai-driven-anti-aging-drug-discovery-platform 2017-04-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2346d910fe983514/fda-approves-bavencio-merck-kgaa-and-pfizer-s-breakthrough-immunotherapy-for-rare-skin-cancer 2017-03-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/65e5aacd10f07740/als-clinical-trials-review-20-years-of-failure-are-we 2017-03-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/62f8e6073c8da793/sandoz-marks-biosimilars-milestone-with-1b-sales-plans-five-major-launches-by-2020 2017-03-06T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b9ad6c0ae57ece8a/novartis-leverages-ai-to-transform-drug-development-decision-making-process 2017-02-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fac36ed3ee598ccb/nice-rejects-alexion-s-kanuma-for-ultra-rare-lal-d-treatment-citing-high-costs 2017-02-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d76c116a086f2286/image-analysis-group-and-alimentiv-form-strategic-partnership-to-advance-ai-driven-gastroenterology-clinical-trials 2017-02-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cf045eb37a422b4f/minimal-residual-disease-predicts-superior-survival-in 2017-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dda3a08bde4696c3/mabvax-therapeutics-expands-phase-i-clinical-trial-for-pancreatic-cancer-treatment 2016-12-05T18:30:42+00:00 weekly 0.7 https://trial.medpath.com/news/2ef9667d3b5c4462/psilocybin-shows-promise-in-reducing-depression-and-anxiety-in-cancer-patients 2016-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a78aeb349480d645/nice-proposes-three-tier-cost-effectiveness-framework-for-drug-evaluation-in-uk 2016-11-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/89a5d40ce90b6f50/fda-approves-rival-diabetes-combinations-xultophy-and-soliqua-for-type-2-diabetes-management 2016-11-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b1b6b23fd3e18f84/gsk-bone-cancer-treatment-granted-fda-breakthrough 2016-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8ef25684e41c06a8/teva-and-ibm-watson-partner-to-accelerate-ai-driven-drug-repurposing-initiative 2016-10-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/72d92c55c003637a/kymab-and-epimab-form-strategic-alliance-to-develop-novel-bispecific-antibodies-for-cancer-treatment 2016-10-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0460e3b808746397/immunotherapy-cancer-drug-nivolumab-hailed-as-game-changer 2016-10-09T06:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/8361a2f5e74c89d6/encouraging-results-for-ribociclib-in-advanced-breast-cancer 2016-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d55f76d4aba43d83/strategic-framework-for-early-asset-development-integrating-clinical-patient-and-commercial-value 2016-10-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/34e83cbea4a9d70e/verily-partners-with-dutch-institutions-to-launch-large-scale-parkinson-s-disease-study 2016-10-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2f3a69c280924589/inspiring-hope-ideathon-launches-global-initiative-to-boost-clinical-trial-participation 2016-09-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/43326322494f85bf/new-immunotherapy-for-leukemia-shows-promise-in-small-clinical-trial 2016-09-21T18:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/8417166304ae2f1d/fda-approves-sandoz-s-erelzi-as-first-enbrel-biosimilar-in-us 2016-08-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/da1ec7c785a7bccc/comprehensive-guide-clinical-trial-regulatory-pathways-across-10-asia-pacific-nations 2016-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a26f0ff555a8a003/study-protocol-for-a-randomized-controlled-non-inferiority-trial-on-blended-depression-treatment-in-europe 2016-08-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b69165854cca02bf/precision-oncology-medicine-the-clinical-relevance-of-patient-specific-biomarkers-used-to-optimize-cancer-treatment 2016-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fbccf708fc07a997/shionogi-announces-acceptance-of-new-drug-application-in-the 2016-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3f18eedc361a192d/an-exploration-of-the-impact-of-initial-timing-of-physical-therapy-on 2016-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4115ae797f1a4436/risk-based-monitoring-revolutionizes-clinical-trial-quality-management 2016-05-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/29e96959168d6859/new-research-reveals-key-strategies-for-identifying-and-engaging-pharmaceutical-industry-s-rising-stars 2016-03-13T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fe3dd479ec12c097/ema-launches-prime-initiative-to-accelerate-access-to-breakthrough-medicines-in-europe 2016-03-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d47c2abce1d25465/a-multi-centre-three-arm-randomised-clinical-trial-viper 2016-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/edb58776a2c2b907/revlimid-lenalidomide-now-fda-approved-as-first-line 2016-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b1cb96c779f6c36e/fda-grants-breakthrough-therapy-designation-for-adaptimmune-s-ny-eso-t-cell-therapy-in-synovial-sarcoma 2016-02-09T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/e04dd78cc8ab2faf/tetanus-shot-enhances-survival-in-brain-tumor-immunotherapy 2016-01-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5808f99f278a7b1e/study-evaluates-intra-arterial-tenecteplase-following-endovascular-therapy-for-acute-stroke 2016-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6f64d7995245a96a/phase-1b-trial-of-dostarlimab-combinations-shows-promise-in-advanced-solid-tumors 2016-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/08ceb3691c9e4ac8/three-new-therapies-approved-for-multiple-myeloma 2016-01-06T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d246d27b5e3106ae/the-reporting-of-adverse-events-in-oncology-phase-iii-trials 2016-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6a721c6b70563eb7/fda-approves-record-45-new-drugs-in-2015-led-by-breakthrough-cancer-immunotherapy-opdivo 2015-12-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0002dacb7c708d05/sanofi-and-boehringer-ingelheim-announce-eur11-4b-asset-swap-deal-to-reshape-consumer-health-market 2015-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8b959c1d6f92660b/novel-cancer-drug-development-pipeline-shows-promise-across-multiple-therapeutic-areas 2015-12-11T13:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/1bcf30fccd6f5cdc/palbociclib-a-new-option-for-front-line-treatment 2015-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/718bccbd42bb6a9d/the-bwel-trial-a-study-on-weight-loss-and-breast-cancer-recurrence 2015-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5931d4580e75e725/fda-approves-trofinetide-for-rett-syndrome-treatment 2015-10-12T20:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/e45282fad1f9dab0/india-modernizes-clinical-trial-process-with-digital-system-and-mandatory-av-consent-recording 2015-10-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/592d49cc93ac2a3c/smoking-poses-heightened-health-risks-for-hiv-patients-studies-show 2015-09-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/90d09e13094f92f4/federal-register-volume-90-issue-4-tuesday-january-7-2025-govinfo 2015-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c9c891a2a9d6a217/fulvestrant-500-mg-versus-anastrozole-1-mg-for-the-first 2015-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5bf0a968cc0445c0/nice-provisionally-approves-biomarin-s-vimizim-for-ultra-rare-morquio-disease-with-real-world-data-requirements 2015-09-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ab5b18ade11943ed/fda-approves-two-new-ustekinumab-biosimilars-bringing-total-us-biosimilar-count-to-65 2015-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e362cebcdea081a1/ropeginterferon-alfa-2b-a-novel-ifna-2b-induces-high 2015-08-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ee9cb324dee74bf8/europe-emerges-as-leading-hub-for-precision-medicine-innovation-and-implementation 2015-08-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7962548256270c5c/astrazeneca-expands-immuno-oncology-portfolio-with-three-strategic-partnerships 2015-08-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e53e6a6cc59ec205/india-revamps-clinical-trial-regulations-to-align-with-global-standards 2015-08-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/99e06d421aef8227/who-welcomes-european-regulators-historic-green-light-for-first-malaria-vaccine 2015-07-24T14:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/d313b9537202d027/palbociclib-for-the-treatment-of-estrogen-receptor 2015-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/08d6554f46485678/modified-herpes-virus-shows-promise-in-phase-3-melanoma-trial-improving-survival-by-20-months 2015-05-27T08:47:54+00:00 weekly 0.7 https://trial.medpath.com/news/3ce26276b1406f56/pancreatic-cancer-action-network-and-perthera-launch-know-your-tumor-initiative-for-precision-treatment 2015-05-07T00:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/59c4f2c5749dd5b6/free-light-chains-in-patients-with-acute-coronary-syndromes 2015-04-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/13b3da77c6f5ed97/novartis-revolutionizes-clinical-trial-recruitment-through-digital-innovation-and-social-media 2015-03-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eb312a6257af6cfa/poly-adp-ribose-polymerase-inhibitors-recent-advances-and-future 2015-03-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/35c23d063bf8c4a0/abbvie-acquires-pharmacyclics-for-21-billion-to-secure-imbruvica-cancer-drug-rights 2015-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5bc1e1f29db0ca99/tyra-biosciences-pipeline-targets 2015-02-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2075524173047cf4/clinical-trials-validate-the-severity-of-persistent-lyme-disease 2015-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/031a743d304a18ec/real-world-evidence-shows-positive-impact-on-hta-drug-approvals-analysis-reveals 2015-01-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/086055ee0af71d95/beyond-the-pill-pharmaceutical-industry-shifts-focus-to-holistic-patient-solutions 2015-01-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1e919f100eb0bd66/navigating-the-35-billion-biosimilar-market-new-marketing-paradigms-for-success 2015-01-06T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/150877374f681295/breakthrough-in-bladder-cancer-treatment-with-new-immunotherapy-drug 2014-11-27T02:25:43+00:00 weekly 0.7 https://trial.medpath.com/news/d9724f8fd2a8dcd5/ucla-gene-therapy-achieves-100-cure-rate-for-bubble-baby-disease-in-clinical-trials 2014-11-18T13:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/62c83a7cf5ea5a04/surpass-et-phase-iii-study-of-ropeginterferon-alfa-2b-versus 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7311c8876a34ba8e/prospective-open-label-single-arm-single-center-follow 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c9c1effc034e0175/topotecan-a-new-active-drug-in-the-second-line-treatment 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5cbfd6f1e4fce24d/psychedelics-for-patients-with-cancer-a-comprehensive-pubmed 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f0e23a30be0edc74/impact-of-pre-transplantation-minimal-residual-disease-mrd-on-the 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c25b7039f893f659/effect-of-landiolol-hydrochloride-an-ultra-short-acting-beta 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/67e9e18240bb225c/abemaciclib-a-potent-cyclin-dependent-kinase-4-and-6-inhibitor-for 2014-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2faca9484b6baa31/persistent-lyme-empiric-antibiotic-study-europe-please-design-of-a 2014-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a2fde03e92e3c5e7/phase-iii-leap-012-study-shows-promising-results-for-intermediate-stage-hcc-treatment 2014-09-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0c67423e5ea6344e/south-korea-emerges-as-premier-clinical-trial-hub-with-20-billion-pharmaceutical-market-potential 2014-09-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b3b7fb3e443d9845/breakthroughs-in-oncology-recent-clinical-trial-findings 2014-09-10T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ceea4a4f8dc9eb6c/comparative-evaluation-of-high-flow-nasal-cannula-and-conventional-o2-therapy-in-pediatric-cardiac-surgical-patients 2014-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f08510a975700f7b/alternatives-to-opioids-in-the-pharmacologic-management 2014-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2dfebc596a2f809/evolving-landscape-of-oncology-clinical-trials-expert-insights-on-precision-medicine-and-patient-recruitment 2014-07-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7b684ff2e65305ab/time-and-motion-studies-emerge-as-critical-tool-for-healthcare-efficiency-assessment 2014-07-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f45711d3b4a69c5c/wales-launches-ps100-million-life-sciences-hub-to-boost-innovation-and-investment 2014-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd2f21a8afe243c6/fda-approves-hpv-dna-test-as-primary-cervical-cancer-screening-alternative-to-pap-smear 2014-04-25T01:41:58+00:00 weekly 0.7 https://trial.medpath.com/news/2663ea9c8cd85a1f/elevated-bone-turnover-markers-predict-poor-survival-in-castration-resistant-prostate-cancer 2014-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/34020ce4a852ce7f/innovative-strategies-for-patient-recruitment-in-rare-disease-trials-lessons-from-the-alkaptonuria-experience 2014-02-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/019e8b8ef7a3527a/strategic-clinical-trial-design-bridging-the-gap-between-regulatory-approval-and-market-access 2014-01-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/41af2b86621dd70b/oasis-diagnostics-receives-michael-j-fox-foundation-grant-for-saliva-based-parkinson-s-test 2014-01-10T04:38:18+00:00 weekly 0.7 https://trial.medpath.com/news/421df68a6b34d510/advancements-in-natural-killer-cell-cancer-immunotherapy 2014-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/991e7bdaf5e1bd55/poly-adp-ribose-polymerase-parp-inhibitors-for-the 2014-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7d06d5cd1af02087/administration-of-the-etonogestrel-contraceptive-implant-on 2013-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2fc4269e19ad6e24/rare-disease-research-faces-critical-funding-gap-despite-scientific-value 2013-10-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f19b2287cd611d45/ruxolitinib-for-myelofibrosis-an-update-of-its-clinical-effects 2013-10-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6e70e7fee718f59b/bristol-myers-squibb-150-years-of-pharmaceutical-innovation-and-global-healthcare-leadership 2013-08-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a3181cdd73b97f90/china-s-healthcare-reform-ambitious-1-trillion-investment-plan-reshapes-market-access-landscape 2013-07-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/462109b7c655b41f/emerging-breakthroughs-in-hematologic-malignancies-expert-highlights-promising-treatments-and-research-directions 2013-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b9f1f5e1dd5c747f/amgen-s-strategic-approach-to-global-pharmacovigilance-balancing-innovation-with-patient-safety 2013-07-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e6ea81bb787307de/navigating-complex-safety-evaluations-in-early-phase-cancer-drug-development 2013-07-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5abe2dbde8739df2/italian-pharmaceutical-market-faces-1-6b-decline-as-government-pushes-generic-drug-adoption 2013-07-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4ce6ff9370e9e96c/european-market-access-hurdles-loom-for-pd-1-pd-l1-immunotherapies-in-oncology 2013-06-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e4b7b37aabae4852/rising-costs-and-success-rates-the-complex-economics-of-oncology-drug-development 2013-06-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4fa76af972850150/4sc-gives-update-on-the-clinical-development-of-its-lead-cancer 2013-05-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d7d3149b59f41ea7/merck-serono-and-quintiles-forge-groundbreaking-5-year-clinical-development-partnership 2013-05-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eef34d6f36cc7f1c/uk-payers-show-flexibility-in-nebulizer-access-despite-limited-clinical-evidence-in-asthma-treatment 2013-04-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3eb97a0a4b2811be/temozolomide-s-effectiveness-in-treating-high-grade-glioma 2013-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bf201d0af662d121/pharma-s-evolution-in-social-media-from-listening-to-collaboration-in-rare-disease-communities 2013-02-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/80e204fff9f8bb59/home-healthcare-services-emerge-as-strategic-priority-for-pharmaceutical-companies 2013-02-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3bbe43d07adc419d/fda-issues-new-draft-guidance-for-early-stage-alzheimer-s-drug-development 2013-02-12T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ecf131a824af5f13/global-push-for-clinical-trial-transparency-gains-momentum-with-ema-and-alltrials-campaign 2013-01-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4b341d23835dc235/gsk-and-biological-e-form-joint-venture-to-develop-novel-six-in-one-pediatric-vaccine 2013-01-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b30f5c9fa181ae8f/cook-medical-s-zilver-ptx-becomes-first-fda-approved-drug-eluting-peripheral-stent-in-u-s-market 2013-01-16T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/4716c8e7330f09e9/novel-extended-release-diphenidol-formulation-reduces-dosing-frequency-while-maintaining-therapeutic-plasma-levels 2013-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/066936af6ff87c0b/biotech-spin-outs-emerge-as-critical-bridge-between-academia-and-pharma-r-d 2012-12-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/34fe8190da7c1459/ema-recommends-approval-of-selincro-for-alcohol-dependency-treatment 2012-12-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5087ecbbe4b3fef3/emotional-marketing-in-pharma-evidence-shows-power-of-combining-rational-and-emotional-appeals 2012-11-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4e712e74d5c43c70/roche-s-journey-from-vitamin-production-pioneer-to-personalized-medicine-leader 2012-10-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/35818222e053945a/prucalopride-in-the-treatment-of-chronic-constipation 2012-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/69524a0748ddba0c/suppl-1-a-reappraisal-of-the-u-s-clinical-trials-of-post-treatment 2012-10-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4cec4cd5a0ddb8ce/sanofi-and-bristol-myers-squibb-restructure-alliance-following-patent-expirations 2012-10-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7820182fbcce6575/study-confirms-efficacy-of-ulipristal-acetate-as-emergency-contraception 2012-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/236ef426e3b4c421/pharma-giants-embrace-open-science-pfizer-merck-lead-industry-transformation 2012-08-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/910e8c714a0d9da4/nih-expert-outlines-critical-challenges-and-solutions-in-rare-disease-clinical-trials 2012-08-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/feb4f109158257d4/strategic-clinical-trial-outsourcing-could-save-pharma-industry-billions-experts-say 2012-07-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2cc46bc8345b29f9/global-clinical-trials-navigating-challenges-and-opportunities-in-modern-drug-development 2012-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0bd833f30944ae96/global-biosimilars-market-set-to-reach-2-3-billion-by-2015-as-industry-faces-development-challenges 2012-04-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d5d37c4382660926/diabetes-treatment-doubles-skin-cancer-drug-s-effectiveness 2012-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dbd72fb57089d9be/global-biosimilars-market-set-to-reach-3-99-billion-by-2017-as-industry-embraces-complex-biologics 2012-03-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/068790f6da825c82/india-s-complex-regulatory-landscape-poses-major-hurdles-for-pharmaceutical-approvals 2012-02-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/713b96cb7d4270df/glucose-dependent-insulinotropic-polypeptide-reduces 2012-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c7a2054aa7c6b903/obinutuzumab-shows-promise-in-treating-proliferative-lupus-nephritis-in-phase-2-trial 2012-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3e1469de13ed042f/barriers-to-personalized-medicine-payer-reimbursement-challenges-slow-diagnostic-test-adoption 2011-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9798b52ff082b86f/advancements-in-car-modified-t-cells-for-leukemia-treatment 2011-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/190d72c0202f50f6/xarelto-okayed-by-fda-for-treating-atrial-fibrillation-cbs-news 2011-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fbe16965cfac673d/lifestyle-and-metformin-interventions-show-significant-benefits-in-diabetes-prevention 2011-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fad35ac7bf3b17db/four-key-drivers-reshaping-successful-oncology-drug-launches-in-modern-market 2011-08-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/45d899a7ea7d2e17/breakthrough-in-lung-cancer-screening-ct-scans-reduce-mortality 2011-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/80e94eed7b887d8c/fda-approves-lialda-for-maintenance-of-remission-in-ulcerative-colitis-patients 2011-07-18T15:41:37+00:00 weekly 0.7 https://trial.medpath.com/news/7d433e2b7def9983/cetuximab-enhances-treatment-efficacy-for-metastatic-colorectal-cancer-with-kras-wild-type 2011-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1622e8879f0a8333/metallic-copper-as-an-antimicrobial-surface-a-comprehensive-review 2010-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f1954538d928f304/global-pharmaceutical-r-d-outsourcing-trends-industry-shifts-toward-strategic-partnerships-and-offshore-operations 2010-09-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/43917559694f1820/urovant-sciences-announces-u-s-fda-approval-of-gemtesa 2010-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bc2a16528222ba27/global-economic-pressures-force-pharmaceutical-industry-to-confront-radical-transformation 2010-05-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/03311e3870a2ad5e/kras-mutation-in-stage-iii-colon-cancer-and-clinical-outcome-following-intergroup-trial-calgb-89803 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3ccb3b7861f189d5/fda-expands-access-to-investigational-drugs-for-treatment-use 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a142b72279c509c1/fda-approves-sanofi-s-multaq-for-atrial-fibrillation-patients-marking-first-new-treatment-in-two-decades 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9a0995b866532e59/nz-scientist-s-gene-research-offers-hope-against-obesity-epidemic 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f11feb249ee74461/fda-issues-guidance-for-cardiovascular-risk-assessment-of-novel-antidiabetic-agents 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/949d1cdae1343fb5/wuxi-pharmatech-strengthens-board-with-strategic-appointments-of-industry-veterans 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/44c3089796ad9c0a/new-cancer-treatment-successes-identified-in-phase-3-trials 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5c73032f4337d376/ku-team-announces-breakthrough-in-leishmaniasis-treatment 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b4d978a49a03b117/study-on-adherence-to-glaucoma-medication-regimens 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2cd18ff6685e4b66/weekly-contraception-with-mifepristone 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f58b800e5d55c55f/progress-and-challenges-in-developing-blood-stage-malaria-vaccines 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d155a8f9006936ce/generalizability-in-two-clinical-trials-of-lyme-disease-pmc 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3997110f29b6d7d5/first-implantable-artificial-heart-gets-fdas-approval 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e7205a67639511c8/new-insights-into-bladder-cancer-screening-and-awareness-campaign-launch 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e9d42338fa01892e/honorhealth-s-cancer-research-program-a-leader-in-clinical-trials-and-treatment-innovation 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/703f3a22a3f3ef3d/study-and-treatment-of-post-lyme-disease-stop-ld 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b32a96e1e5e2ef01/fda-approves-expanded-use-of-med-el-cochlear-implant-system 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d9c1f71157e0f4fd/home-based-exercise-program-significantly-reduces-knee-pain-study-finds 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a82c09937f9b8179/roche-s-cphpc-drug-shows-promise-in-breaking-down-alzheimer-s-amyloid-clumps 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4a01baaf424a9e8a/culturally-tailored-interventions-boost-cervical-cancer-screening-among-chinese-women-in-north-america 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1e7738c609d91ca1/new-drug-treatment-beating-ovarian-cancer 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a26d6b6256b29df3/early-antithymocyte-globulin-therapy-enhances-survival-in-steroid-resistant-acute-gvhd-patients 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d1ce22d5051238a4/asco-2024-lenvatinib-plus-pembrolizumab-shows-superiority-over-sunitinib-in-advanced-renal-cell-carcinoma 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/53dcfc4172d7dd37/fda-approves-pembrolizumab-for-advanced-esophageal-squamous-cell-cancer-with-pd-l1-expression 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cc76ed55b06e6771/regional-chemotherapy-for-liver-metastases-of-colorectal-cancer-shows-varied-perfusion-patterns 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3c49a3173747e172/regional-chemotherapy-shows-promise-in-treating-colorectal-cancer-metastatic-to-the-liver 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2ebffb1994b2e7c0/d3bio-s-novel-kras-g12c-inhibitor-shows-promising-results-in-phase-1-cancer-trial 2010-01-01T00:00:00+00:00 weekly 0.7